Drug maker Lupin Friday said it has received the US health regulator's approval to market a generic version of Sanofi Aventis' Rifadin capsules, used to treat tuberculosis, in the American market.
Lupin Pharmaceuticals Inc, the Mumbai-based firm's US-based subsidiary, has received final approval from US Food and Drug Administration (USFDA) for its Rifampin Capsules in 150 mg and 300 mg strengths, Lupin said in a statement.
Rifampin Capsules are indicated for the treatment of all forms of tuberculosis.
It is also prescribed for the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx.
As per the IMS sales data, Rifadin Capsules had annual US sales of around $18.5 million.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app